Effects of everolimus on cytokines, oxidative stress, and renal histology in ischemia-reperfusion injury of the kidney.
BACKGROUND
To evaluate the effects of everolimus on renal ischemia-reperfusion injury (IRI).


METHODS
Wistar albino rats were divided into control, ischemia-reperfusion (IR), and ischemia-reperfusion/everolimus (IR/eve) groups. Everolimus was administered for seven consecutive days to the IR/eve group prior to injury. IR and IR/eve groups underwent forty-five minutes ischemia followed by the application of reperfusion at 2 and 24 hours. Blood samples and kidneys were taken from all animals.


RESULTS
. Serum blood urea nitrogen and creatinine levels increased at two hours of reperfusion in the IR and IR/eve groups, and decreased at 24 hours of reperfusion in the IR group. In the IR/eve group, we detected significantly high interleukin-6 levels and low tumor necrosis factor-alpha and malondialdehyde levels at 24 hours. Myeloperoxidase levels increased at two hours of reperfusion in the IR/eve group, but decreased significantly at 24 hours. Everolimus did not improve renal tubular and interstitial injuries in renal IRI.


CONCLUSIONS
It has been demonstrated that pretreatment with everolimus has beneficial effects on cytokines and oxidative stress in renal IRI. However, these effects are insufficient for the correction of histopathological changes and restoration of normal kidney function.
Suyani
Elif
E
Gazi University, Department of Internal Medicine, 06510, Besevler, Ankara, Turkey. elifsuyani@hotmail.com
Derici
Ulver Boztepe
UB
Sahin
Tolga
T
Ofluoglu
Ebru
E
Pasaoglu
Hatice
H
Erdem
Ozlem
O
Barit
Gonca
G
Reis
Kadriye Altok
KA
Erten
Yasemin
Y
Arinsoy
Turgay
T
Sindel
Sukru
S
D000818:Animals; D016207:Cytokines / Q000378:metabolism*; D000068338:Everolimus; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D007674:Kidney Diseases / Q000473:pathology / Q000628:therapy*; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000473:pathology / Q000628:therapy*; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*
D016207:Cytokines; D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus